Literature DB >> 17124507

Novel mutations in the BHD gene and absence of loss of heterozygosity in fibrofolliculomas of Birt-Hogg-Dubé patients.

Maurice A M van Steensel1, Valerie L R M Verstraeten, Jorge Frank, Nicole W J Kelleners-Smeets, Pamela Poblete-Gutiérrez, Dominique Marcus-Soekarman, Reno S Bladergroen, Peter M Steijlen, Michel van Geel.   

Abstract

Birt-Hogg-Dubé (BHD) syndrome is an autosomal-dominantly inherited cancer syndrome characterized by fibrofolliculomas, lung cysts leading to pneumothorax, and chromophobic/oncocytic renal cell carcinoma. The disease is caused by heterozygous mutations in the BHD gene encoding folliculin and all mutations reported putatively lead to protein truncation. Although the function of folliculin is unknown, it is thought to be a tumor suppressor, with loss of heterozygosity (LOH) initiating tumor formation. Here, we report on four novel BHD gene mutations, including two splice-site mutations, in patients presenting with skin lesions only. We further show that LOH cannot be detected in fibrofolliculomas from three patients, suggesting that for the manifestation of cutaneous tumors in BHD syndrome haplo-insufficiency of folliculin is sufficient to initiate uncontrolled growth. Renal microscopic oncocytosis in BHD is considered as a precursor to malignant kidney tumors and may likewise be the result of haplo-insufficiency, with somatic second-hit mutations or LOH giving rise to malignancy later in life.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17124507     DOI: 10.1038/sj.jid.5700592

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  30 in total

1.  Loss of heterozygosity at the FLCN locus in early renal cystic lesions in dogs with renal cystadenocarcinoma and nodular dermatofibrosis.

Authors:  Tina B Bønsdorff; Johan H Jansen; Ragnar F Thomassen; Frode Lingaas
Journal:  Mamm Genome       Date:  2009-04-23       Impact factor: 2.957

2.  The folliculin mutation database: an online database of mutations associated with Birt-Hogg-Dubé syndrome.

Authors:  Ming-Hui Wei; Patrick W Blake; Julia Shevchenko; Jorge R Toro
Journal:  Hum Mutat       Date:  2009-09       Impact factor: 4.878

3.  Genetic screening of the FLCN gene identify six novel variants and a Danish founder mutation.

Authors:  Maria Rossing; Anders Albrechtsen; Anne-Bine Skytte; Uffe B Jensen; Lilian B Ousager; Anne-Marie Gerdes; Finn C Nielsen; Thomas vO Hansen
Journal:  J Hum Genet       Date:  2016-10-13       Impact factor: 3.172

4.  [Facial papules and pneumothoraces. Birt-Hogg-Dubé syndrome].

Authors:  V Lichte; S Hanneken; P A Gerber; M van Geel; J Frank
Journal:  Hautarzt       Date:  2012-10       Impact factor: 0.751

5.  Neuroendocrine carcinoma in a patient with Birt-Hogg-Dubé syndrome.

Authors:  Tijs Claessens; Sherry A Weppler; Michel van Geel; David Creytens; Maaike Vreeburg; Bradley Wouters; Maurice A M van Steensel
Journal:  Nat Rev Urol       Date:  2010-09-14       Impact factor: 14.432

6.  Birt-Hogg-Dubé: tumour suppressor function and signalling dynamics central to folliculin.

Authors:  Andrew R Tee; Arnim Pause
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

Review 7.  Pulmonary manifestations of Birt-Hogg-Dubé syndrome.

Authors:  Nishant Gupta; Kuniaki Seyama; Francis X McCormack
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

8.  Mutations of the Birt Hogg Dube gene in patients with multiple lung cysts and recurrent pneumothorax.

Authors:  Yoko Gunji; Taeko Akiyoshi; Teruhiko Sato; Masatoshi Kurihara; Shigeru Tominaga; Kazuhisa Takahashi; Kuniaki Seyama
Journal:  J Med Genet       Date:  2007-05-11       Impact factor: 6.318

9.  Second hits in the FLCN gene in a hereditary renal cancer syndrome in dogs.

Authors:  Tina B Bønsdorff; Johan Høgset Jansen; Frode Lingaas
Journal:  Mamm Genome       Date:  2008-01-25       Impact factor: 2.957

10.  Birt-Hogg-Dubé syndrome: from gene discovery to molecularly targeted therapies.

Authors:  Laura S Schmidt
Journal:  Fam Cancer       Date:  2013-09       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.